205 related articles for article (PubMed ID: 21247220)
1. Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.
Brown BA; Torabi M
Drug Saf; 2011 Feb; 34(2):117-23. PubMed ID: 21247220
[TBL] [Abstract][Full Text] [Related]
2. Peri-infusional adverse reactions to rituximab in patients with non-Hodgkin's lymphoma.
Arredondo-Garza T; Majluf-Cruz A; Vela-Ojeda J; Mariscal-Ramírez I; Solis-Anaya L; Lopez-Gutiérrez JR; Guadarrama CH; Rico-Curiel E; Armenta-San Sebastián JA; Castañeda-Hernández G
Arch Med Res; 2013 Oct; 44(7):549-54. PubMed ID: 24120421
[TBL] [Abstract][Full Text] [Related]
3. Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
Vukusic S; Brassat D; de Seze J; Izquierdo G; Lysandropoulos A; Moll W; Vanopdenbosch L; Arque MJ; Kertous M; Rufi P; Oreja-Guevara C
Mult Scler Relat Disord; 2019 Apr; 29():7-14. PubMed ID: 30654246
[TBL] [Abstract][Full Text] [Related]
4. Rapid infusion with rituximab: short term safety in systemic autoimmune diseases.
Larsen JL; Jacobsen S
Rheumatol Int; 2013 Feb; 33(2):529-33. PubMed ID: 22068354
[TBL] [Abstract][Full Text] [Related]
5. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.
Mayer L; Kappos L; Racke MK; Rammohan K; Traboulsee A; Hauser SL; Julian L; Köndgen H; Li C; Napieralski J; Zheng H; Wolinsky JS
Mult Scler Relat Disord; 2019 May; 30():236-243. PubMed ID: 30844611
[TBL] [Abstract][Full Text] [Related]
6. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience.
Can M; Alibaz-Öner F; Yılmaz-Öner S; Atagündüz P; İnanç N; Direskeneli H
Clin Rheumatol; 2013 Jan; 32(1):87-90. PubMed ID: 23053686
[TBL] [Abstract][Full Text] [Related]
7. Immediate infusional reactions to intravenous immunobiological agents for the treatment of autoimmune diseases: experience of 2126 procedures in a non-oncologic infusion centre.
Moss IB; Moss MB; dos Reis DS; Coelho RM
Rev Bras Reumatol; 2014; 54(2):102-9. PubMed ID: 24878856
[TBL] [Abstract][Full Text] [Related]
8. Stevens-Johnson syndrome after treatment with rituximab.
Lowndes S; Darby A; Mead G; Lister A
Ann Oncol; 2002 Dec; 13(12):1948-50. PubMed ID: 12453865
[TBL] [Abstract][Full Text] [Related]
9. The incidence and risk factors of infusion-related reactions to rituximab for treating B cell malignancies in a single tertiary hospital.
Jung JW; Kang HR; Lee SH; Cho SH
Oncology; 2014; 86(3):127-34. PubMed ID: 24480856
[TBL] [Abstract][Full Text] [Related]
10. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Tony HP; Burmester G; Schulze-Koops H; Grunke M; Henes J; Kötter I; Haas J; Unger L; Lovric S; Haubitz M; Fischer-Betz R; Chehab G; Rubbert-Roth A; Specker C; Weinerth J; Holle J; Müller-Ladner U; König R; Fiehn C; Burgwinkel P; Budde K; Sörensen H; Meurer M; Aringer M; Kieseier B; Erfurt-Berge C; Sticherling M; Veelken R; Ziemann U; Strutz F; von Wussow P; Meier FM; Hunzelmann N; Schmidt E; Bergner R; Schwarting A; Eming R; Hertl M; Stadler R; Schwarz-Eywill M; Wassenberg S; Fleck M; Metzler C; Zettl U; Westphal J; Heitmann S; Herzog AL; Wiendl H; Jakob W; Schmidt E; Freivogel K; Dörner T;
Arthritis Res Ther; 2011 May; 13(3):R75. PubMed ID: 21569519
[TBL] [Abstract][Full Text] [Related]
12. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.
Schwartzberg LS; Stepanski EJ; Fortner BV; Houts AC
Support Care Cancer; 2008 Apr; 16(4):393-8. PubMed ID: 17909865
[TBL] [Abstract][Full Text] [Related]
13. Serious infusion-related reaction after rituximab, abatacept and tocilizumab in rheumatoid arthritis: prospective registry data.
Salmon JH; Perotin JM; Morel J; Dramé M; Cantagrel A; Ziegler LE; Ravaud P; Sibilia J; Pane I; Mariette X; Gottenberg JE;
Rheumatology (Oxford); 2018 Jan; 57(1):134-139. PubMed ID: 29069471
[TBL] [Abstract][Full Text] [Related]
14. Rituximab Faster Infusion for Patients With Non-Hodgkin's Lymphoma in the United States: Implications for Nursing Practice.
Dawson K
J Infus Nurs; 2015; 38 Suppl 6():S4-S10. PubMed ID: 26536411
[TBL] [Abstract][Full Text] [Related]
15. [Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia].
Šimkovič M; Vodárek P; Motyčková M; Žák P; Smolej L
Vnitr Lek; 2015; 61(7-8):626-32. PubMed ID: 26375688
[TBL] [Abstract][Full Text] [Related]
16. The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial.
Kitahiro Y; Yamamoto K; Yakushijin K; Ioroi T; Tanda M; Itohara K; Omura T; Minami H; Yano I
JMIR Res Protoc; 2024 Feb; 13():e54882. PubMed ID: 38386393
[TBL] [Abstract][Full Text] [Related]
17. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.
Dale RC; Brilot F; Duffy LV; Twilt M; Waldman AT; Narula S; Muscal E; Deiva K; Andersen E; Eyre MR; Eleftheriou D; Brogan PA; Kneen R; Alper G; Anlar B; Wassmer E; Heineman K; Hemingway C; Riney CJ; Kornberg A; Tardieu M; Stocco A; Banwell B; Gorman MP; Benseler SM; Lim M
Neurology; 2014 Jul; 83(2):142-50. PubMed ID: 24920861
[TBL] [Abstract][Full Text] [Related]
18. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
19. Rituximab use in pediatric central demyelinating disease.
Beres SJ; Graves J; Waubant E
Pediatr Neurol; 2014 Jul; 51(1):114-8. PubMed ID: 24768216
[TBL] [Abstract][Full Text] [Related]
20. Rituximab faster infusion for patients with non-Hodgkin's lymphoma in the United States: implications for nursing practice.
Dawson K
J Infus Nurs; 2013; 36(3):172-8. PubMed ID: 23558916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
